Clinical Trial Update: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) [Phase 4]

View source ↗

Summary

Phase 4 trial update on whether the naltrexone ER and bupropion ER combination (Contrave/Mysimba) influences major adverse cardiovascular events in people with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Contrave/Mysimba (Naltrexone hydrochloride ER and Bupropion hydrochloride ER)

Snippet

Sponsor: Currax Pharmaceuticals | Conditions: Obesity | Phase 4 | Status: ACTIVE_NOT_RECRUITING